Status of adjuvant endocrine therapy for breast cancer

@inproceedings{Schiavon2014StatusOA,
  title={Status of adjuvant endocrine therapy for breast cancer},
  author={Gaia Schiavon and Ian E. Smith},
  booktitle={Breast Cancer Research},
  year={2014}
}
Adjuvant endocrine therapy reduces the risk of recurrence and death from breast cancer in women with hormone receptor-positive early breast cancer. Tamoxifen has been the standard therapy for decades, and this is still the case for pre-menopausal women. Ovarian suppression is of similar efficacy but currently there is no strong evidence for adding this to tamoxifen and the additional morbidity can be considerable. Results from two important trials addressing this issue are imminent. In post… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk

Breast Cancer Research and Treatment • 2017
View 5 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 114 references

Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2012
View 9 Excerpts
Highly Influenced

On behalf of the aTTom Collaborative Group: aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 in 6,953 women with early breast cancer

RG Gray, D Rea, +17 authors M Lee
2013
View 3 Excerpts
Highly Influenced

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

Journal of the National Cancer Institute • 2012
View 19 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…